| 61.87 -2.53 (-3.93%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 78.19 | 1-year : | 84.8 |
| Resists | First : | 66.94 | Second : | 72.6 |
| Pivot price | 67.12 |
|||
| Supports | First : | 57.79 | Second : | 48.08 |
| MAs | MA(5) : | 66.44 |
MA(20) : | 66.06 |
| MA(100) : | 58.77 |
MA(250) : | 46.01 |
|
| MACD | MACD : | 0.6 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 20.2 |
D(3) : | 41.6 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 77 | Low : | 24.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRCT ] has closed below the lower bollinger band by 3.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ PRCT ] is to continue within current trading range. Bollinger Bands are 3.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 65.58 - 65.97 | 65.97 - 66.27 |
| Low: | 60.63 - 61.13 | 61.13 - 61.5 |
| Close: | 61.21 - 61.95 | 61.95 - 62.5 |
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Fri, 26 Jul 2024
PROCEPT BioRobotics Co. (NASDAQ:PRCT) Stock Position Lifted by ProShare Advisors LLC - Defense World
Thu, 25 Jul 2024
PROCEPT BioRobotics (PRCT) to Release Earnings on Thursday - MarketBeat
Wed, 24 Jul 2024
With 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional owners - Yahoo Finance
Thu, 18 Jul 2024
PROCEPT BioRobotics Announces Board Chairperson Transition - TipRanks
Tue, 16 Jul 2024
A Closer Look at 4 Analyst Recommendations For PROCEPT BioRobotics - Markets Insider
Mon, 15 Jul 2024
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 51 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 83.6 (%) |
| Shares Short | 5,040 (K) |
| Shares Short P.Month | 4,430 (K) |
| EPS | -2.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.13 |
| Profit Margin | -66.2 % |
| Operating Margin | -62.1 % |
| Return on Assets (ttm) | -20.4 % |
| Return on Equity (ttm) | -47.3 % |
| Qtrly Rev. Growth | 82.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.04 |
| EBITDA (p.s.) | -2.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -104 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -29.19 |
| PEG Ratio | -1.7 |
| Price to Book value | 12.03 |
| Price to Sales | 20.35 |
| Price to Cash Flow | -30.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|